187 related articles for article (PubMed ID: 21518927)
1. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway.
Martinelli P; Bonetti P; Sironi C; Pruneri G; Fumagalli C; Raviele PR; Volorio S; Pileri S; Chiarle R; McDuff FK; Tusi BK; Turner SD; Inghirami G; Pelicci PG; Colombo E
Blood; 2011 Jun; 117(24):6617-26. PubMed ID: 21518927
[TBL] [Abstract][Full Text] [Related]
2. Aberrant anaplastic lymphoma kinase activity induces a p53 and Rb-dependent senescence-like arrest in the absence of detectable p53 stabilization.
McDuff FK; Turner SD
PLoS One; 2011 Mar; 6(3):e17854. PubMed ID: 21423761
[TBL] [Abstract][Full Text] [Related]
3. E2FBP1 antagonizes the p16(INK4A)-Rb tumor suppressor machinery for growth suppression and cellular senescence by regulating promyelocytic leukemia protein stability.
Fukuyo Y; Takahashi A; Hara E; Horikoshi N; Pandita TK; Nakajima T
Int J Oral Sci; 2011 Oct; 3(4):200-8. PubMed ID: 22010578
[TBL] [Abstract][Full Text] [Related]
4. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
5. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease.
Omura-Minamisawa M; Diccianni MB; Chang RC; Batova A; Bridgeman LJ; Schiff J; Cohn SL; London WB; Yu AL
Clin Cancer Res; 2001 Nov; 7(11):3481-90. PubMed ID: 11705866
[TBL] [Abstract][Full Text] [Related]
6. p16Ink4a suppression of lung adenocarcinoma by Bmi-1 in the presence of p38 activation.
Lee MO; Lee HJ; Kim MA; Kim EK; Lee JH; Heo JH; Lee SH; Cho SH; Fornace AJ; Jeong HC; Cha HJ
J Thorac Oncol; 2011 Mar; 6(3):423-31. PubMed ID: 21164364
[TBL] [Abstract][Full Text] [Related]
7. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
Blood; 2007 Sep; 110(5):1621-30. PubMed ID: 17416736
[TBL] [Abstract][Full Text] [Related]
8. Melanin accumulation accelerates melanocyte senescence by a mechanism involving p16INK4a/CDK4/pRB and E2F1.
Bandyopadhyay D; Medrano EE
Ann N Y Acad Sci; 2000 Jun; 908():71-84. PubMed ID: 10911949
[TBL] [Abstract][Full Text] [Related]
9. Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest.
Sheahan S; Bellamy CO; Dunbar DR; Harrison DJ; Prost S
BMC Cancer; 2007 Nov; 7():215. PubMed ID: 18021445
[TBL] [Abstract][Full Text] [Related]
10. [Cyclin dependent kinase inhibitors and replicative senescence].
Gerland LM; Ffrench M; Magaud JP
Pathol Biol (Paris); 2001 Dec; 49(10):830-9. PubMed ID: 11776695
[TBL] [Abstract][Full Text] [Related]
11. Re-expression of endogenous p16ink4a in oral squamous cell carcinoma lines by 5-aza-2'-deoxycytidine treatment induces a senescence-like state.
Timmermann S; Hinds PW; Münger K
Oncogene; 1998 Dec; 17(26):3445-53. PubMed ID: 10030668
[TBL] [Abstract][Full Text] [Related]
12. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
13. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
[TBL] [Abstract][Full Text] [Related]
14. Requirements for cell cycle arrest by p16INK4a.
Bruce JL; Hurford RK; Classon M; Koh J; Dyson N
Mol Cell; 2000 Sep; 6(3):737-42. PubMed ID: 11030353
[TBL] [Abstract][Full Text] [Related]
15. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.
Schmitt CA; Fridman JS; Yang M; Lee S; Baranov E; Hoffman RM; Lowe SW
Cell; 2002 May; 109(3):335-46. PubMed ID: 12015983
[TBL] [Abstract][Full Text] [Related]
16. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.
Møller MB; Kania PW; Ino Y; Gerdes AM; Nielsen O; Louis DN; Skjødt K; Pedersen NT
Leukemia; 2000 May; 14(5):898-904. PubMed ID: 10803523
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.
Gorgoulis VG; Zacharatos P; Kotsinas A; Liloglou T; Kyroudi A; Veslemes M; Rassidakis A; Halazonetis TD; Field JK; Kittas C
Am J Pathol; 1998 Dec; 153(6):1749-65. PubMed ID: 9846966
[TBL] [Abstract][Full Text] [Related]
18. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
[TBL] [Abstract][Full Text] [Related]
19. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
[TBL] [Abstract][Full Text] [Related]
20. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
Chiarle R; Gong JZ; Guasparri I; Pesci A; Cai J; Liu J; Simmons WJ; Dhall G; Howes J; Piva R; Inghirami G
Blood; 2003 Mar; 101(5):1919-27. PubMed ID: 12424201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
